Ulka N. Vaishampayan

25.3k total citations · 5 hit papers
495 papers, 12.8k citations indexed

About

Ulka N. Vaishampayan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ulka N. Vaishampayan has authored 495 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 339 papers in Pulmonary and Respiratory Medicine, 239 papers in Oncology and 147 papers in Molecular Biology. Recurrent topics in Ulka N. Vaishampayan's work include Renal cell carcinoma treatment (185 papers), Prostate Cancer Treatment and Research (114 papers) and Cancer Immunotherapy and Biomarkers (98 papers). Ulka N. Vaishampayan is often cited by papers focused on Renal cell carcinoma treatment (185 papers), Prostate Cancer Treatment and Research (114 papers) and Cancer Immunotherapy and Biomarkers (98 papers). Ulka N. Vaishampayan collaborates with scholars based in United States, Canada and United Kingdom. Ulka N. Vaishampayan's co-authors include Toni K. Choueiri, Brian I. Rini, Maha Hussain, Georg A. Bjarnason, Daniel Y.C. Heng, Frede Donskov, Lori Wood, David F. McDermott, Sumanta K. Pal and Neeraj Agarwal and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ulka N. Vaishampayan

471 papers receiving 12.6k citations

Hit Papers

Nivolumab for Metastatic ... 2013 2026 2017 2021 2014 2013 2018 2021 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →
  2. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
    2013 730 citations Ulka N. Vaishampayan, Neeraj Agarwal et al. profile →
  3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. profile →
  4. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Ulka N. Vaishampayan et al. profile →
  5. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
    2021 170 citations Sumanta K. Pal, Catherine M. Tangen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulka N. Vaishampayan United States 56 7.3k 5.7k 5.0k 3.1k 2.8k 495 12.8k
Bohuslav Melichar Czechia 51 6.7k 0.9× 6.3k 1.1× 5.4k 1.1× 3.8k 1.2× 1.5k 0.5× 503 13.2k
Christian Kollmannsberger Canada 63 8.7k 1.2× 4.8k 0.8× 5.5k 1.1× 3.4k 1.1× 4.2k 1.5× 387 14.0k
Sergio Bracarda Italy 38 7.6k 1.0× 4.4k 0.8× 5.8k 1.2× 3.8k 1.2× 2.1k 0.7× 236 11.6k
Laurence Albigès France 54 10.7k 1.5× 5.1k 0.9× 6.5k 1.3× 4.2k 1.3× 2.1k 0.8× 460 14.4k
Primo N. Lara United States 60 8.5k 1.2× 7.0k 1.2× 6.0k 1.2× 3.5k 1.1× 1.5k 0.5× 458 16.3k
Sumanta K. Pal United States 65 8.7k 1.2× 8.0k 1.4× 6.9k 1.4× 4.4k 1.4× 4.2k 1.5× 741 17.4k
Elizabeth R. Plimack United States 50 6.3k 0.9× 7.9k 1.4× 3.6k 0.7× 2.4k 0.8× 5.8k 2.1× 317 14.1k
Nicholas D. James United Kingdom 51 7.1k 1.0× 4.7k 0.8× 3.1k 0.6× 2.5k 0.8× 3.2k 1.1× 344 13.6k
Vivek Subbiah United States 54 4.6k 0.6× 6.0k 1.0× 3.7k 0.7× 3.1k 1.0× 1.7k 0.6× 599 12.2k
Jacek Jassem Poland 59 8.0k 1.1× 11.4k 2.0× 4.8k 1.0× 3.9k 1.2× 3.3k 1.2× 523 19.9k

Countries citing papers authored by Ulka N. Vaishampayan

Since Specialization
Citations

This map shows the geographic impact of Ulka N. Vaishampayan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulka N. Vaishampayan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulka N. Vaishampayan more than expected).

Fields of papers citing papers by Ulka N. Vaishampayan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulka N. Vaishampayan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulka N. Vaishampayan. The network helps show where Ulka N. Vaishampayan may publish in the future.

Co-authorship network of co-authors of Ulka N. Vaishampayan

This figure shows the co-authorship network connecting the top 25 collaborators of Ulka N. Vaishampayan. A scholar is included among the top collaborators of Ulka N. Vaishampayan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulka N. Vaishampayan. Ulka N. Vaishampayan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, David C., Elisabeth I. Heath, Frank C. Cackowski, et al.. (2025). Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP). JCO Precision Oncology. 9(9). e2500457–e2500457.
2.
Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations
3.
Vaishampayan, Ulka N., et al.. (2024). Clinical Applications of the Gut Microbiome in Genitourinary Cancers. American Society of Clinical Oncology Educational Book. 44(3). e100041–e100041. 2 indexed citations
4.
Vaishampayan, Ulka N., Randy F. Sweis, Deepak Kilari, et al.. (2024). Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.. Journal of Clinical Oncology. 42(16_suppl). 2507–2507. 1 indexed citations
5.
Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations
6.
Staehler, Michael, et al.. (2023). Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.. Journal of Clinical Oncology. 41(6_suppl). 651–651. 2 indexed citations
7.
Vaishampayan, Ulka N., Archana Thakur, Wei Chen, et al.. (2022). Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(1). 122–133. 21 indexed citations
8.
Dudek, Arkadiusz Z., Dejan Juric, Afshin Dowlati, et al.. (2021). 476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results. Regular and Young Investigator Award Abstracts. A505–A506. 10 indexed citations
9.
Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations
10.
Martini, Jean-François, Elizabeth R. Plimack, Toni K. Choueiri, et al.. (2020). Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 26(21). 5598–5608. 16 indexed citations
11.
Bergerot, Cristiane Decat, Errol J. Philip, Paulo Gustavo Bergerot, et al.. (2020). Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 127(3). 354–358. 22 indexed citations
12.
McDermott, Ray, Emmanuel S. Antonarakis, Christopher Hoimes, et al.. (2020). KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). European Urology Open Science. 19. e885–e886. 2 indexed citations
13.
Hahn, Andrew W., David D. Stenehjem, Anitha Alex, et al.. (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology Seminars and Original Investigations. 37(6). 352.e19–352.e24. 2 indexed citations
14.
Jones, Richard F., Joyce Reyes, Heather M. Gibson, et al.. (2019). An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice. Cancer Immunology Immunotherapy. 68(7). 1143–1155. 2 indexed citations
15.
Vaishampayan, Ulka N., Izabela Podgorski, Lance K. Heilbrun, et al.. (2018). Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 25(2). 652–662. 3 indexed citations
16.
Goff, Laura W., Nilofer S. Azad, Stacey Stein, et al.. (2018). Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Investigational New Drugs. 37(2). 315–322. 13 indexed citations
17.
Joseph, Richard W., Gurkamal Chatta, & Ulka N. Vaishampayan. (2017). Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Urologic Oncology Seminars and Original Investigations. 35(4). 142–148. 12 indexed citations
18.
Gibson, Heather M., Jesse Veenstra, Richard Jones, et al.. (2015). Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunology Research. 3(7). 777–786. 11 indexed citations
19.
Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 33(13). 1430–1437. 865 indexed citations breakdown →
20.
Jiménez, Rafael E., Maha Hussain, Fernando J. Bianco, et al.. (2001). Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.. PubMed. 7(8). 2440–7. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bohuslav Melichar Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Laurence Albigès Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by Sumanta K. Pal Breakdown of academic impact, for papers by Elizabeth R. Plimack Breakdown of academic impact, for papers by Nicholas D. James Breakdown of academic impact, for papers by Vivek Subbiah Breakdown of academic impact, for papers by Jacek Jassem
Rankless by CCL
2026